Enhancing the peripheral chemoreflex to protect the newborn against hypoxic injury – A translational study based on fetal sheep model of birth asphyxia
Description of the granted funding
Severe birth asphyxia is a major cause of newborn mortality and in survivors birth asphyxia can cause life-long consequences that can manifest as neurologic morbidities. Birth asphyxia implies a decrease in systemic oxygenation and accumulation of pCO2 in fetal circulation. Typically during labor birth asphyxia develops if reperfusion time between uterine contractions is inadequate or placental function is suboptimal. If the newborn suffers from birth asphyxia, therapeutic hypothermia is the treatment of choice. In this study, we propose a new treatment to minimize the asphyxia-related brain abnormalities and improve long-term neurologic outcome. We test whether acetazolamide medication when given to the asphyxiated newborn will improve outcome. Studies on rats and mice have shown that acetazolamide significantly improves tissue oxygenation and inhibits seizure activity. We use fetal sheep model to test, if this drug can prevent newborn short- and long-term neurologic problems.
Show moreStarting year
2021
End year
2023
Granted funding
Other information
Funding decision number
342826
Fields of science
Genetics, developmental biology, physiology
Research fields
Kehitysbiologia ja fysiologia
Identified topics
gynecology, pediatrics